Potassium-Sparing Diuretics Market Share

  • Report ID: 3292
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Potassium-Sparing Diuretics Market - Regional Analysis

North American Market Insights

North America industry is poised to dominate majority revenue share of 39% by 2035, The growth of the market can be attributed primarily to the increasing prevalence of cardiovascular diseases and the increasing demand for safe and effective medicines. The increasing acceptance of new technologies and the growing number of clinical trials for the development of new drugs and treatments as well as the growing investments in research and development activities by pharmaceutical and biotechnological companies, are also expected to aid in the growth of the market. A total of USD 83 billion was spent on R&D by the pharmaceutical industry in 2019 in the United States. Also, from 2010 to 2019, 59 novel drugs were approved for sale, a 60 percent increase over the previous decade. Companies are investing in research and development activities in order to develop newer and more effective potassium-sparing diuretics that can help those suffering from illnesses such as hypertension, congestive heart failure, and edema. Furthermore, the rising number of initiatives taken by governments and private organizations to create awareness about cardiovascular diagnostics and their treatments, are expected to fuel regional market growth.

APAC Market Insights

The Asia Pacific potassium-sparing diuretics market is estimated to be the second largest, registering a share of about 25% by the end of 2035. The growth of the market can be attributed majorly to the increasing populace of geriatrics suffering from chronic kidney diseases as well as hypertension and other cardiovascular diseases. The study indicated that the overall self-reported prevalence of diagnosed CVDs was 30% for older adults aged 45 and above in India. Also, as per WHO, China's population is ageing at the fastest rate in the world. Chinese citizens over 60 are expected to reach 28% by 2040. As people age, they often develop hypertension and other conditions that require diuretics to manage water retention. Potassium-sparing diuretics are preferred for elderly individuals as they are gentler on the kidneys and help retain potassium levels, which are important for proper functioning of the heart and other organs. In addition, increasing health awareness and initiatives by governments to control the prevalence of diabetes and hypertension, and the growing focus on preventive healthcare are expected to contribute to the growth of the Asia Pacific potassium-sparing diuretics market in the near future.

Europe Market Insights

Further, the potassium-sparing diuretics market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of this market can be attributed to the rising prevalence of lifestyle diseases such as hypertension and diabetes. A growing awareness of early diagnosis and treatment options among regional populations is expected to boost demand for potassium-sparing diuretics. As people become more aware of the early signs of kidney disease, they are more likely to seek medical attention and treatment. Potassium-sparing diuretics are becoming increasingly popular as they help to reduce the risk of developing kidney disease.

Potassium-Sparing Diuretics Market size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of potassium-sparing diuretics is estimated at USD 129.39 million.

The global potassium-sparing diuretics market size crossed USD 122.87 million in 2025 and is likely to register a CAGR of over 5.9%, exceeding USD 217.97 million revenue by 2035.

By 2035, North America is anticipated to capture a 39% share of the potassium-sparing diuretics market, stemming from the increasing prevalence of cardiovascular diseases and the rising demand for safe and effective medicines.

Key players in the market include Pfizer Inc., Merck Sharp & Dohme Corp., Accord Healthcare, Amneal Pharmaceuticals LLC, Centaur Pharmaceuticals Pvt. Ltd., Validus Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., CMP Pharma, Boehringer Ingelheim GmbH, Bayer AG.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos